Ever heard of the wonderful healing properties of the amniotic membrane? For nearly a century, amniotic membranes have been considered a highly effective treatment for chronic and non- healing wounds. And experts say the magic is all in the tissue. The amniotic membrane is the innermost, avascular layer of the fetal membrane, which consists of the epithelium, basement membrane, and the stroma. Collected from the placental tissue of a full-term pregnancy (37 to 42 weeks of gestation) and treated with antibiotics after collection, each of these layers contains properties that play a crucial role in healing. One of the layers contains fetal hyaluronic acid and cytokines that can be used to reduce inflammation. Medically termed the HC-HA/PTX3 complex, it is a unique extracellular matrix that has anti-scarring, anti-inflammatory, and regenerative benefits. 1 2 3 4 5
Today, HC- HA/PTX3 is recognised worldwide for its powerful role in wound healing, tissue repair, ophthalmology, and more. Through this blog, you will understand how this complex function derived from the amniotic membrane is gaining importance in modern healthcare. 3 4
|
Key Takeaways
|
What is HC-HA/PTX3 Complex?
Heavy Chain- Hyaluronan/Pentraxin 3, abbreviated as HC-HA/PTX3 complex, is a unique naturally occurring extracellular matrix found in the human amniotic membrane, i.e., the placental tissue and umbilical cord. It is studied worldwide for its tissue- regenerative properties. It consists of three primary components.
- Heavy Chains (HC) are proteins derived from inter-alpha trypsin inhibitor molecules.
- Hyaluronic Acid (HA) is a naturally occurring glycosaminoglycan that provides hydration, structural support, and promotes tissue repair.
- Pentraxin 3 (PTX3) is a protein that is involved in regulating inflammation and immune responses.
Together, these molecules form a biologically active matrix that plays a vital role in maintaining tissue homeostasis and supports regenerative processes. Unlike traditional treatments that look at managing symptoms, HC-HA/PTX3 influences the body's healing response at a cellular level.
How the Complex is Formed
Like all biological processes, the formation of HC-HA/PTX3 is an organised process that occurs naturally within the fetal tissues, specifically the amniotic membrane. The complex is created following a biochemical reaction that is accelerated by a protein known as TSG-6, which is a tumour necrosis factor- stimulated gene-6.
The process is as follows:
- Heavy chain 1 from the blood protein inter-α-trypsin inhibitor (IαI) is transferred to a high-molecular-weight strand of Hyaluronan (HA)
- The HA, or hyaluronan, serves as the structural backbone and scaffold of the complex
- PTX3, i.e., Pentraxin 3 molecules, then bind tightly to the HC-HA strand
This process results in the formation of the HC-HA/PTX3 complex that is capable of modulating inflammation, controlling immune responses, and supporting tissue regeneration. Owing to its presence within the amniotic membrane, these tissues exhibit healing properties that minimise fibrosis and scar formation.
Key Clinical Benefits
Due to its healing abilities, HC-HA/PTX3 is being researched actively in regenerative medicine, specifically for wound care and ophthalmology. Its therapeutic benefits include:
1. Reduces Inflammation
A striking characteristic of HC-HA/PTX3 is its ability to regulate inflammation. During tissue injury, excessive inflammation can delay healing and result in tissue damage.
HC-HA/PTX3 helps to suppress inflammatory signals while promoting a healing response. This reduces tissue destruction and encourages quicker recovery.
2. Prevents Scarring
One of the most common challenges after an injury or surgery is fibrosis and scarring. The HC-HA/PTX3 complex has demonstrated the ability to inhibit the activation of fibroblasts and myofibroblasts. These are cells that are responsible for scar tissue formation.
By reducing excessive fibrosis, HV-HA/PTX3 supports functional tissue repair and improved outcomes.
3. Regulates Immune Cell Activity
HC-HA/PTX3 does not completely suppress the immune system; it regulates immune cell activity to promote a regulated immune response that protects tissues while minimising inflammation.
This is particularly important in sensitive issues like an eye or a chronic wound.
4. Promotes Tissue Regeneration
HC-HA/PTX3 is an extracellular matrix known for providing accelerated healing. The matrix provides appropriate structural and biochemical support for cellular migration, proliferation, and differentiation that support the repair, restoration,n and regeneration of tissues.
HC-HA/PTX3 reduces discomfort and improves patient recovery across several clinical applications by controlling inflammation and promoting tissue repair.
Primary Clinical Applications
HC-HA/PTX3 has wide-ranging benefits that make it a preferred choice for targeted therapies. Particularly because of its ability to mitigate inflammation and suppress scar tissue, it is considered an important biological active compound that can be used in:
1. Ophthalmology
HC-HA/PTX3 membrane products are predominantly used for a variety of ocular surface and retinal diseases. The anti- inflammatory and regenerative properties can help restore the ocular surface integrity while reducing scarring. They are most commonly used for:
- Corneal epithelial defects
- Dry eye disease
- Ocular surface inflammation
- Chemical injuries to the eye
- Post- surgery ocular healing
OptiCover from Cellution Biologics is a lyophilised amniotic membrane graft and is an example of an HC-HA/PTX3 preserving product used for corneal epithelial defects, dry eye disease, and ocular surface inflammation. This includes cases like superficial punctate keratitis and early- stage neurotrophic keratitis.
2. Chronic Wound Management
HC-HA/PTX3 amniotic membrane therapies are used for several difficult-to-heal wounds, such as:
- Diabetic foot ulcers
- Venous leg ulcers
- Pressure injuries
- Surgical wounds
HC-HA/PTX3 products can help wound closure, reduce inflammation, and create a conducive environment for tissue regeneration.
AmchoPlast, an amnion- chorion membrane allograft, and AmCoreMatrix (hospital-use counterpart) are examples of HC-HA/PTX3 preserving grafts used to support closure in diabetic foot ulcers, venous ulcers, and pressure injuries.
3. Surgical & Orthopaedic Applications
HC-HA/PTX3 helps minimise scar tissue formation and support post- surgery healing. Research is also exploring applications in orthopaedic and musculoskeletal conditions where the anti- adhesion and anti- fibrotic characteristics of HV-HA/PTX3 can be used for inflammation control and tissue regeneration. In the surgical setting, amnion-chorion grafts for hospital use like AmCoreMatrix are used to support post- surgical wound closure. They are also used to minimise adhesion formation.
Safety & Processing Standards
The effectiveness of HC-HA/PTX3 depends a lot on the way the tissue is processed and preserved. Improper handling can compromise the integrity of the extracellular matrix and reduce the biological activity. To create high-quality amniotic membrane products, the following conditions must be met:
- Sourced from carefully screened donors
- Processed under stringent quality standards
- Use of advanced preservation techniques that help retain the structural and functional properties of HC-HA/PTX3
Therefore, donor screening, regulatory compliance, and manufacturing processes remain critical factors in delivering reliable Amniotic Membrane Therapy products.
Future Potential of HC-HA/PTX3
There's a lot of growing scientific evidence that continues to explore the therapeutic applications of HC-HA/PTX3. Researchers are investigating its role in advanced wound care, ophthalmology, tissue engineering, and regenerative medicine, targeting a wider range of inflammatory conditions.
As researchers continue to explore regenerative medicine, HC-HA/PTX3 is expected to stay and evolve as a primary biological component driving next-gen treatments. Its unique ability to regulate inflammation, minimise scarring and support faster tissue repair positions it as a valuable tool for improving outcomes for patients.
By preserving and utilising the natural regenerative properties of the amniotic membrane, HC-HA/PTX3 represents a crucial advancement in the pursuit of effective wound management options.
